Teva Pharmaceutical Industries Ltd. $TEVA Shares Sold by Emerald Advisers LLC

Emerald Advisers LLC reduced its stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 12.9% in the second quarter, HoldingsChannel reports. The fund owned 41,035 shares of the company’s stock after selling 6,062 shares during the quarter. Emerald Advisers LLC’s holdings in Teva Pharmaceutical Industries were worth $688,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Ion Asset Management Ltd. raised its holdings in shares of Teva Pharmaceutical Industries by 6.5% in the 1st quarter. Ion Asset Management Ltd. now owns 39,033,500 shares of the company’s stock worth $599,945,000 after purchasing an additional 2,383,500 shares in the last quarter. Phoenix Financial Ltd. increased its stake in shares of Teva Pharmaceutical Industries by 31.7% during the 2nd quarter. Phoenix Financial Ltd. now owns 37,761,444 shares of the company’s stock worth $632,882,000 after purchasing an additional 9,094,372 shares during the last quarter. Menora Mivtachim Holdings LTD. increased its stake in shares of Teva Pharmaceutical Industries by 2.8% during the 1st quarter. Menora Mivtachim Holdings LTD. now owns 29,189,316 shares of the company’s stock worth $448,640,000 after purchasing an additional 808,074 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. boosted its holdings in shares of Teva Pharmaceutical Industries by 8.9% during the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 28,685,422 shares of the company’s stock worth $480,768,000 after buying an additional 2,350,000 shares during the period. Finally, Harel Insurance Investments & Financial Services Ltd. boosted its holdings in shares of Teva Pharmaceutical Industries by 197,885.2% during the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 22,055,547 shares of the company’s stock worth $338,989,000 after buying an additional 22,044,407 shares during the period. 54.05% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. JPMorgan Chase & Co. raised their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the stock an “overweight” rating in a report on Friday, October 3rd. Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Saturday, October 11th. UBS Group lifted their price target on shares of Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the stock a “buy” rating in a research report on Wednesday, September 24th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research note on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Teva Pharmaceutical Industries currently has an average rating of “Buy” and an average target price of $25.57.

Teva Pharmaceutical Industries Stock Up 2.1%

Shares of NYSE TEVA opened at $20.20 on Thursday. The firm has a market cap of $23.16 billion, a PE ratio of -126.22, a price-to-earnings-growth ratio of 1.09 and a beta of 0.71. The company has a 50 day simple moving average of $19.21 and a 200 day simple moving average of $17.45. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.06 and a quick ratio of 0.77. Teva Pharmaceutical Industries Ltd. has a 1 year low of $12.47 and a 1 year high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Wednesday, July 30th. The company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.64 by $0.02. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 46.10%. The company had revenue of $4.18 billion during the quarter, compared to the consensus estimate of $4.34 billion. During the same quarter last year, the firm posted $0.61 EPS. The company’s quarterly revenue was up .3% on a year-over-year basis. On average, research analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current year.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, insider Placid Jover sold 6,053 shares of Teva Pharmaceutical Industries stock in a transaction on Friday, August 1st. The shares were sold at an average price of $15.16, for a total transaction of $91,763.48. Following the transaction, the insider directly owned 6,774 shares of the company’s stock, valued at $102,693.84. The trade was a 47.19% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Eric A. Hughes sold 52,742 shares of Teva Pharmaceutical Industries stock in a transaction on Friday, August 1st. The stock was sold at an average price of $15.16, for a total value of $799,568.72. The disclosure for this sale is available in the SEC filing. 0.49% of the stock is owned by insiders.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.